It is always a thrill and a privilege to share our customers' success stories with you, particularly when they feature ABclonal's products in their research publications. Over the past year, we have seen many citations of our reagents in multiple journals, showcasing the partnership ABclonal maintains as a trusted lab partner across a wide range of disciplines. In this entry, we will highlight some of the catalog and custom antibody products our valued customers used to generate recent publication-quality research that adds to our collective understanding of biology!

As a scientist (or at least, a guy who likes science and works for a bioscience-oriented company), I am invested in the power of scientific research in improving the quality of human life across all arenas. It is particularly gratifying when our customers, who are all primarily research scientists, derive direct benefit from ABclonal's products in their published research. In this case, our business development director had a customer recently defend her thesis based on a publication that used several ABclonal catalog antibodies. I enjoyed reading her group's article that may lead to more effective treatment strategies for diabetes patients going forward, so let's get to it.

December is a month of holidays and celebration, but it is also a time to raise awareness for a global epidemic that has lasted over four decades. During World HIV/AIDS Awareness Month, health organizations, including the United States Department of Veteran Affairs, serve to remind everyone about the importance of getting tested, to remember those who succumbed to the disease, and to improve access to advanced therapies.

Since its first identification and description in 1981, medical advances have offered effective therapies to keep the virus at bay, and in some cases even completely cure a patient of the human immunodeficiency virus, or HIV, and to prevent it from becoming the acquired immunodeficiency syndrome, or AIDS, which is often catastrophic to the patient. Unfortunately, as of 2021 per the World Health Organization (WHO), there are still over 38 million people living with HIV, with approximately 1.5 million new infections and 650,000 HIV-related deaths. Much of this has to do with lack of education or proper infrastructure and often obstacles to accessibility for treatment and prevention. I hope to explore HIV with you during this month of awareness so we can do our part to mitigate this persistent epidemic.

A common experimental strategy in studying the effects of a specific protein in cells or organisms is to remove it. One can determine the physiological outcomes in the absence of that protein to ascertain its relative importance in maintaining normal functions, or in some cases, to note that it is dispensable or redundant and might have a backup within the cell to take up the slack. Some targeted techniques include RNA interference (RNAi) and CRISPR-based gene editing, and in many cases, it is possible to generate knockout cell lines or even organisms, like mice, that cannot express a specific protein. But when those strategies are not feasible for the experiment at hand, what is one to do?

The 2021 Nobel Prize in Physiology of Medicine was awarded jointly to David Julius, of the University of California at San Francisco, and Ardem Patapoutian, a neuroscience researcher at the Scripps Research Institute in La Jolla, California. Working independently, Julius and Patapoutian discovered the key receptors (TRPV1, TRPM8, Piezo1, and Piezo2) in our bodies that sense heat, cold, and touch. Their work not only helps us to understand how we perceive and adapt to the surrounding world, but also paves the way for drug discoveries that target a wide range of diseases, including chronic pain, respiratory disease, and cancer.

Cancer remains one of the most prevalent and deadly diseases affecting humanity. According to the Centers For Disease Control, cancer was the second leading cause of death in 2020 for Americans behind heart disease. The American Cancer Society projects at least 600,000 deaths due to cancer each year, despite the fact that mortality continues to decrease each year. The majority of these deaths are from advanced cancer, which are cancers that do not respond well to treatment and therefore cannot be cured. It is when the advanced cancer progresses to a point where it can escape the primary tumor site, a process known as metastasis, that the prognosis becomes grim.